Thus preliminary results of herpesvirus-based OV armed with GM-CSF, pseudotyped by envelope fusogenic glycoprotein of gibbon ape leukemia virus (GALV-GP-R) [72] and combined with nivolumab showed that three of the four anti-PD1 refractory melanoma patients were responding to treatment, as were five of the six non-melanoma skin cancer patients (with three complete responses). The gene discussed is CSF2; the disease is melanoma.